Nov 1, 2025

TCX-201 poster at PEGS Europe 2025 in Lisbon

Poster A116 on TCX-201 at the Protein & Antibody Engineering Summit, November 11–13, 2025.

Announcement of Tacalyx poster A116 on TCX-201 at PEGS Europe 2025 in Lisbon

Tacalyx presents TCX-201 at PEGS Europe 2025, the Protein & Antibody Engineering Summit at the Lisbon Congress Center, November 11–13, 2025.

TCX-201, a Novel ADC Targeting a Specific Tumor-Associated Carbohydrate Antigen (TACA) with Excellent Preclinical Efficacy, PK and Safety Profile in Solid Tumor Models.

Dr. Francesco Muraca, Head of Cell Biology, and Dr. Stephan Grunwald, Head of Biochemistry. Poster A116, morning poster sessions on November 12 and 13.

More news

All news

Apr 29, 2026 Press releases

Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic

€11 million from the existing syndicate in a first closing of the seed extension. TCX-201 is selected as first clinical candidate, with a CTA filing planned for 2027.

AACR 2026 poster 5631 on TCX-201, with in vitro, in vivo, pharmacokinetic and toxicology panels

Apr 21, 2026 Scientific presentations

TCX-201 and TCX-101 data presented at AACR 2026

Two posters at the AACR Annual Meeting 2026 in San Diego: the preclinical profile of first clinical candidate TCX-201 (Poster 5631) and TCX-101 as a trispecific T-cell engager (Poster 5584).

Tacalyx April 2026 highlights flyer listing the Scientific Advisory Board meeting in Berlin and the AACR partnering event in San Diego

Apr 9, 2026 Company

April 2026: advisory boards, AACR partnering and two posters

Scientific Advisory Board meeting in Berlin, Clinical Advisory Board meeting and AACR Oncology Industry Partnering Event in San Diego, followed by two posters at AACR 2026.